AU2017214761B2 - Proteinaceous compounds and uses therefor - Google Patents

Proteinaceous compounds and uses therefor Download PDF

Info

Publication number
AU2017214761B2
AU2017214761B2 AU2017214761A AU2017214761A AU2017214761B2 AU 2017214761 B2 AU2017214761 B2 AU 2017214761B2 AU 2017214761 A AU2017214761 A AU 2017214761A AU 2017214761 A AU2017214761 A AU 2017214761A AU 2017214761 B2 AU2017214761 B2 AU 2017214761B2
Authority
AU
Australia
Prior art keywords
pkc
amino acid
cell
proteinaceous molecule
acid residues
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2017214761A
Other languages
English (en)
Other versions
AU2017214761A1 (en
Inventor
Peter MILBURN
Sudha RAO
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Epiaxis Therapeutics Pty Ltd
Original Assignee
Epiaxis Therapeutics Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2016900314A external-priority patent/AU2016900314A0/en
Application filed by Epiaxis Therapeutics Pty Ltd filed Critical Epiaxis Therapeutics Pty Ltd
Publication of AU2017214761A1 publication Critical patent/AU2017214761A1/en
Assigned to EPIAXIS THERAPEUTICS PTY LTD reassignment EPIAXIS THERAPEUTICS PTY LTD Request for Assignment Assignors: UNIVERSITY OF CANBERRA
Application granted granted Critical
Publication of AU2017214761B2 publication Critical patent/AU2017214761B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/11—Protein-serine/threonine kinases (2.7.11)
    • C12Y207/11013—Protein kinase C (2.7.11.13)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Enzymes And Modification Thereof (AREA)
AU2017214761A 2016-02-01 2017-02-01 Proteinaceous compounds and uses therefor Active AU2017214761B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2016900314A AU2016900314A0 (en) 2016-02-01 Proteinaceous compounds and uses therefor
AU2016900314 2016-02-01
PCT/AU2017/050083 WO2017132728A1 (en) 2016-02-01 2017-02-01 Proteinaceous compounds and uses therefor

Publications (2)

Publication Number Publication Date
AU2017214761A1 AU2017214761A1 (en) 2018-08-02
AU2017214761B2 true AU2017214761B2 (en) 2024-02-01

Family

ID=59499146

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2017214761A Active AU2017214761B2 (en) 2016-02-01 2017-02-01 Proteinaceous compounds and uses therefor

Country Status (8)

Country Link
US (1) US10487115B2 (enExample)
EP (1) EP3411061A4 (enExample)
JP (2) JP7341451B2 (enExample)
CN (2) CN116082457A (enExample)
AU (1) AU2017214761B2 (enExample)
CA (1) CA3011870A1 (enExample)
SG (1) SG11201806122YA (enExample)
WO (1) WO2017132728A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202004167XA (en) * 2017-11-08 2020-06-29 Epiaxis Therapeutics Pty Ltd Immunogenic compositions and uses therefor

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015039187A1 (en) * 2013-09-18 2015-03-26 University Of Canberra Stem cell modulation ii

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4873192A (en) 1987-02-17 1989-10-10 The United States Of America As Represented By The Department Of Health And Human Services Process for site specific mutagenesis without phenotypic selection
DE69634084T2 (de) 1995-06-07 2005-12-08 Inex Pharmaceuticals Corp. Herstellung von lipid-nukleinsäure partikeln duch ein hydrophobische lipid-nukleinsäuree komplexe zwischenprodukt und zur verwendung in der gentransfer
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
WO1997030035A1 (en) 1996-02-13 1997-08-21 Zeneca Limited Quinazoline derivatives as vegf inhibitors
PT885198E (pt) 1996-03-05 2002-06-28 Astrazeneca Ab Derivados de 4-anilinoquinazolina
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
EP1002091B1 (en) 1997-07-09 2012-02-29 Coridon Pty Limited Nucleic acid sequence and method for selectively expressing a protein in a target cell or tissue
AUPP807899A0 (en) 1999-01-08 1999-02-04 University Of Queensland, The Codon utilization
WO2000036083A2 (en) 1998-12-17 2000-06-22 La Jolla Institute For Allergy And Immunology Pkc-interacting cousin of trx (picot) polypeptides, polynucleotides, and methods of making and using them
GB9900334D0 (en) 1999-01-07 1999-02-24 Angiogene Pharm Ltd Tricylic vascular damaging agents
GB9900752D0 (en) 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
AU2001258628A1 (en) 2000-05-31 2001-12-11 Astrazeneca Ab Indole derivatives with vascular damaging activity
BR0112225A (pt) 2000-07-07 2003-05-06 Angiogene Pharm Ltd Composto, composição farmacêutica, uso de um composto, e, processo papa preparar um composto
MXPA02012905A (es) 2000-07-07 2004-07-30 Angiogene Pharm Ltd Derivados de colquinol como agentes de dano vascular..
WO2002010193A1 (en) 2000-07-31 2002-02-07 Dabur Research Foundation Lipid-peptide conjugates for treatment of cancer
EP1515964A1 (en) 2002-06-14 2005-03-23 ALTANA Pharma AG Substituted diaminopyrimidines
US20070072281A1 (en) * 2003-02-28 2007-03-29 Gabriele Rummel Three-dimensional structure of the catalytic domain of protein kinase c theta, methods and uses thereof
EP1734991A4 (en) 2004-04-14 2012-10-24 Avirid Inc COMPOSITIONS COMPRISING MODIFIED NUCLEASES DIRECTED AGAINST VIRAL NUCLEIC ACIDS AND METHODS OF USE FOR THE PREVENTION AND TREATMENT OF VIRAL DISEASES
US20100168034A1 (en) 2006-02-20 2010-07-01 Ewha University-Industry Collaboration Foundation Peptide having cell membrane penetrating activity
JP2013545453A (ja) * 2010-11-01 2013-12-26 ユニバーシティ・オブ・テクノロジー、シドニー 免疫変調剤およびそれらの使用
AU2012228365A1 (en) * 2011-03-11 2013-09-19 Katholieke Universiteit Leuven, K.U.Leuven R&D Molecules and methods for inhibition and detection of proteins
JP6550333B2 (ja) 2012-09-27 2019-07-24 ザ ユニヴァーシティ オヴ ブリティッシュ コロンビア ペプチドに誘導されたタンパク質ノックダウン
EP3185858A4 (en) 2014-08-25 2017-12-27 University of Canberra Compositions for modulating cancer stem cells and uses therefor

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015039187A1 (en) * 2013-09-18 2015-03-26 University Of Canberra Stem cell modulation ii

Also Published As

Publication number Publication date
CA3011870A1 (en) 2017-08-10
JP2019506167A (ja) 2019-03-07
JP7341451B2 (ja) 2023-09-11
CN116082457A (zh) 2023-05-09
SG11201806122YA (en) 2018-08-30
WO2017132728A1 (en) 2017-08-10
EP3411061A4 (en) 2019-07-10
AU2017214761A1 (en) 2018-08-02
US20190040103A1 (en) 2019-02-07
JP2022023949A (ja) 2022-02-08
CN108883155A (zh) 2018-11-23
EP3411061A1 (en) 2018-12-12
US10487115B2 (en) 2019-11-26

Similar Documents

Publication Publication Date Title
AU2019207534B2 (en) Proteinaceous molecules and uses therefor
AU2006291541B2 (en) Cell-permeable peptide inhibitors of the JNK signal transduction pathway
KR102373603B1 (ko) 섬유증 억제 활성을 가지는 펩티드 및 이를 포함하는 조성물
US7662786B2 (en) Dolastatin 15 derivatives
AU7938200A (en) Cell-permeable peptide inhibitors of the jnk signal transduction pathway
US9757473B2 (en) Cell-penetrating peptide and conjugate comprising same
ES2319454T9 (es) Péptidos con permeabilidad celular inhibidores de la ruta de transducción de señales de la JNK
WO2011044374A1 (en) Capcna peptide therapeutics for cancer
CN102140473A (zh) 抗肿瘤的核酸与多肽及其应用
AU2017214761B2 (en) Proteinaceous compounds and uses therefor
US20240294587A1 (en) K-ras inhibitor
KR100409264B1 (ko) 세포내 신호전달을 교란시키는 합성 펩티드
US20240228543A1 (en) Cyclic peptide inhibitors of usp22
KR20250138134A (ko) 표적 단백질 분해자 및 세포 투과 펩타이드를 포함하는 융합 분자 및 이의 용도
AU2012203529B2 (en) Cell-Permeable Peptide Inhibitors of the JNK Signal Transduction Pathway
HK1118841B (en) Cell-permeable peptide inhibitors of the jnk signal transduction pathway

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: EPIAXIS THERAPEUTICS PTY LTD

Free format text: FORMER APPLICANT(S): UNIVERSITY OF CANBERRA

FGA Letters patent sealed or granted (standard patent)